Medical and surgical treatment of inflammatory bowel disease in the province of Albacete.
DOI:
https://doi.org/10.19230/jonnpr.2016.1.4.1027Keywords:
Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease, Therapeutics.Abstract
Objective: To analyze the different types of surgery and medical treatments used in patients with inflammatory bowel disease in the
province of Albacete.
Methods: Observational cross-sectional study in which patients from the department of general surgery hospital in Albacete diagnosed
with inflammatory bowel disease in a period of 7 years were included. A review of medical records was performed. Variables studied:
sex, age at diagnosis, age at first surgery, medical history, drug treatment, type of surgery (elective or emergency), reason for
emergency surgery, surgical technique, types of postoperative complications, presence of malignancy and days of hospital stay.
Results: 43 patients were operated. 55.8% were men. 39.5% were diagnosed with ulcerative colitis, and the remaining 60.5% of
Crohn's disease. The most commonly used medical treatments were azathioprine in CD and mesalazine in UC. The first surgery was
around 35 years. The EC was the most surgeries scheduled and urgently required, and the main reason for this latest was the drilling
of small bowel. In UC main surgical treatment was total colectomy, while in EC was the ileocolic resection.
Conclusions: Intestinal perforation is the main reason for surgery in inflammatory bowel disease.
Downloads
References
Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S,et al. World Gastroenterology Organization
Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010;16(1):112-24.
Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007
Mar;117(3):514-21.
Podolsky DK. Inflammatory bowel disease. New Engl J Med 2002;347:417-429.
García de Tena J, Espinosa LM, Alvarez-Mon M. Inflammatory bowel disease. N Engl J Med. 2002 Dec
;347(24):1982-4.
Shivananda S, Lennard-Jones J, Logan R, et al. – Incidente of inflammatory bowel disease across Europe: is
there a. Gut 1996; 39:690-7.
Fumery M, Dauchet L, Vignal C, Gower-Rousseau C. Epidemiology, risk factors and factors associated with
disabling course in inflammatory bowel disease. Rev Prat. 2014 Nov:64(9):1210-5.
López-Serrano P, Pérez-Calle JL, Carrera-Alonso E, Pérez-Fernández T, Rodríguez-Caravaca G, Boixeda-de-
Miguel D, et al. Epidemiologic study on the current incidence of inflammatory bowel disease in Madrid. Rev Esp
Enferm Dig. 2009;101(11):768-72.
Lakatos PL, Szalay F, Tulassay Z, Molnar T, Kovacs A, Gasztonyi B, Papp J, Lakatos L; Hungarian IBD Study
Group. Clinical presentation of Crohn's disease. association between familial disease, smoking, disease
phenotype, extraintestinal manifestations and need for surgery. Hepatogastroenterology. 2005 May-
Jun;52(63):817-22.
López Rubio MA, Tárraga López PJ, Rodríguez Montes JA, Frías López MC, Solera Albero J, Bermejo López P.
Alteración del perfil lipídico y del riesgo cardiovascular en pacientes con Hipotiroidismo subclínico. JONNPR.
;1(2):45-49. DOI: DOI: 10.19230/jonnpr.2016.1.2.970
Fraga XF, Vergara M, Medina C, Casellas F, Bermejo B, Malagelada JR. Effects of smoking on the presentation
and clinical course of inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997;9:683-687.
Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140(6).1807-16.
Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a
population-based study. Cancer. 2001;91(4):854-62.
Fiochi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;182-205.
Bernstein CN, Blanchard JF, Rawsthorne P, et al. Epidemiology of Crohn´s disease and ulcerative colitis in a
central Canadian province: a population-based study. Am J Epidemiol. 1999;149:916-924.
Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, et al.; American College of
Gastroenterology IBD Task Force. An evidence-based systematic review on medical therapies for inflammatory
bowel disease. Am J Gastroenterol. 2011;106 Suppl 1:S2-25.
Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology.
;140(6):1827-1837.e2.
Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al.; IBD Section of the British Society of
Gastroenterology.Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60(5):571-
Ford AC, Achkar JP, Khan KJ, Kane SV, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in ulcerative
colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):601-16.
Berg DF, Bahadursingh AM, Kaminski DL, Longo WE. Acute surgical emergencies in inflammmatory bowel
disease. Am J Surg. 2002 Jul;184(1): 45-51.
Millán Scheiding M, Rodriguez Moranta F, Kreisler Moreno E, Golda T, Fraccalvieri D, Biondo S. Estado actual
del tratamiento quirúrgico electivo de la colitis ulcerosa. Revisión sistemática. Cir Esp. 2012 Nov;90(9):548-57.
Blumberg D, Beck DE. Surgery for ulcerative colitis. Gastroenterol Clin North Am 2002;31(1):219-35.
Hwang JM, Varma MG. Surgery for inflammatory bowel disease. World J Gastroenterol. 2008;14:2678-90.
Lewis RT, Maron DJ. Efficacy and complications of surgery for Crohn´s disease. Gastroenterol Hepatol (N Y).
Sept;6(9):587-96.
Tárraga López PJ, Rodríguez Montes JA. ¿Se deben publicar los resultados negativos o no positivos?.
JONNPR.2016;1(2):43-44.DOI: 10.19230/jonnpr. 2016. 1.2. 928
Published
Issue
Section
License
All accepted originals remain the property of JONNPR. In the event of publication, the authors exclusively transfer their rights of reproduction, distribution, translation and public communication (by any sound, audiovisual or electronic medium or format) of their work. To do so, the authors shall sign a letter transferring these rights when sending the paper via the online manuscript management system.
The articles published in the journal are freely used under the terms of the Creative Commons BY NC SA license, therefore.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
